A Study to Evaluate Pharmacokinetic and Safety Trial of Emraclidine in Participants With Renal Impairment Compared With Participants With Normal Renal Function

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 24, 2023

Primary Completion Date

December 19, 2024

Study Completion Date

December 19, 2024

Conditions

Renal Impairment

Interventions

DRUG

Emraclidine

Oral tablets

Trial Locations (5)

Orlando, Florida, Orlando

Miami, Florida, Miami

Miami, Florida, Miami

Knoxville, Tennessee, Knoxville

Tustin, California, Tustin